NTX-2001 Alcohol Use Disorder Study (NCT07520292)
Summary
NLM registered clinical trial NCT07520292, a Phase 1/2 study evaluating NTX-2001 for alcohol use disorder treatment. The trial is sponsored by Newleos Pharma with enrollment managed by Yale University investigators. The study aims to assess safety and efficacy of the investigational product in adult participants.
What changed
NLM registered a new clinical trial on ClinicalTrials.gov for NTX-2001, an investigational product for alcohol use disorder. The trial is listed as Phase 1/2 with Newleos as sponsor and Yale University conducting the study.
Pharmaceutical companies and research institutions should note this registration for competitive intelligence on AUD treatment development. The registry entry provides public transparency on ongoing clinical research in this therapeutic area.
What to do next
- Monitor ClinicalTrials.gov for enrollment updates
- Review protocol for potential partnership opportunities
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NLM.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.